ATE443518T1 - Vermittler von igel-signalpfaden, zusammensetzungen und relevante verwendungszwecke - Google Patents

Vermittler von igel-signalpfaden, zusammensetzungen und relevante verwendungszwecke

Info

Publication number
ATE443518T1
ATE443518T1 AT02763383T AT02763383T ATE443518T1 AT E443518 T1 ATE443518 T1 AT E443518T1 AT 02763383 T AT02763383 T AT 02763383T AT 02763383 T AT02763383 T AT 02763383T AT E443518 T1 ATE443518 T1 AT E443518T1
Authority
AT
Austria
Prior art keywords
hedgehog
function
providers
compositions
signal paths
Prior art date
Application number
AT02763383T
Other languages
English (en)
Inventor
Lee Rubin
Oivin Guicherit
Stephen Price
Edward A Boyd
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Application granted granted Critical
Publication of ATE443518T1 publication Critical patent/ATE443518T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal Substances (AREA)
AT02763383T 2001-07-27 2002-07-29 Vermittler von igel-signalpfaden, zusammensetzungen und relevante verwendungszwecke ATE443518T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30844901P 2001-07-27 2001-07-27
US33803101P 2001-11-13 2001-11-13
PCT/US2002/024073 WO2003011219A2 (en) 2001-07-27 2002-07-29 Mediators of hedgehog signaling pathways, compositions and uses related thereto

Publications (1)

Publication Number Publication Date
ATE443518T1 true ATE443518T1 (de) 2009-10-15

Family

ID=26976260

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02763383T ATE443518T1 (de) 2001-07-27 2002-07-29 Vermittler von igel-signalpfaden, zusammensetzungen und relevante verwendungszwecke

Country Status (17)

Country Link
US (2) US8354397B2 (de)
EP (1) EP1482928B1 (de)
JP (1) JP4658473B2 (de)
KR (1) KR20040031782A (de)
CN (1) CN1638765A (de)
AT (1) ATE443518T1 (de)
AU (1) AU2002327390B2 (de)
BR (1) BR0211513A (de)
CA (1) CA2455100C (de)
DE (1) DE60233823D1 (de)
EA (1) EA007339B1 (de)
IL (1) IL159858A0 (de)
MX (1) MXPA04000803A (de)
NO (1) NO20040342L (de)
NZ (1) NZ530580A (de)
PL (1) PL366799A1 (de)
WO (1) WO2003011219A2 (de)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998035020A2 (en) 1997-02-10 1998-08-13 The Presidents And Fellows Of Harvard College Methods for modulating hematopoiesis and vascular growth
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
ES2623711T3 (es) 2000-10-13 2017-07-12 Curis, Inc. Antagonistas de hedgehog, procedimientos y usos relacionados con los mismos
US7708998B2 (en) 2000-10-13 2010-05-04 Curis, Inc. Methods of inhibiting unwanted cell proliferation using hedgehog antagonists
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
AU2003234733B2 (en) 2002-04-17 2009-01-29 Cytokinetics, Inc. Compounds, compositions, and methods
DE60322869D1 (de) * 2002-04-22 2008-09-25 Univ Johns Hopkins Modulatoren von hedgehog signalpfaden, zusammensetzungen und verwandte verwendungen
JP2005533119A (ja) 2002-07-17 2005-11-04 サイトキネティクス・インコーポレーテッド 化合物、組成物、及び方法
TWI276631B (en) * 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
JP4726235B2 (ja) 2003-04-17 2011-07-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 癌の処置のためのチェックポイントキナーゼｃｄｓ１（ｃｈｋ２）インヒビターとしての２−フェニル−ベンズイミダゾールおよび２−フェニル−イミダゾ−‘４，５！−ピリジン誘導体
WO2005030206A1 (en) * 2003-09-24 2005-04-07 Imclone Systems Incorporated Aryl-1,3-azole derivatives and methods for inhibiting heparnase activity
DK1730280T3 (en) 2004-03-26 2019-02-04 Curis Inc RNA interference modulators for hedgehog signaling and applications thereof
EP1824832B1 (de) 2004-06-30 2011-04-27 Janssen Pharmaceutica NV Arylsubstituiertes benzimidazol- und imidazopyridinether als wirkstoffe gegen krebs
DK1789390T3 (da) 2004-09-02 2012-02-27 Genentech Inc Pyridyl-inhibitorer af hedgehog-signalering
EP1807074B1 (de) 2004-11-03 2013-10-23 Curis, Inc. Mediatoren von hedgehog-signalwegen, zusammensetzungen und verwendungen in zusammenhang damit
WO2006094246A2 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. N-arylmethyl benzamide sirtuin modulators
JP2008535790A (ja) * 2005-03-03 2008-09-04 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュインモジュレーターであるｎ−フェニルベンズアミド誘導体
WO2006124780A2 (en) * 2005-05-12 2006-11-23 Kalypsys, Inc. Ih-benzo [d] imidazole compounds as inhibitors of b-raf kinase
US8093401B2 (en) 2005-08-04 2012-01-10 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
US8088928B2 (en) * 2005-08-04 2012-01-03 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
EP1910385B1 (de) * 2005-08-04 2013-07-24 Sirtris Pharmaceuticals, Inc. Benzothiazole und thiazolopyridine als sirtuinmodulatoren
US7855289B2 (en) 2005-08-04 2010-12-21 Sirtris Pharmaceuticals, Inc. Sirtuin modulating compounds
JP5129149B2 (ja) 2005-10-31 2013-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を処置および診断するための組成物および方法
US7625759B2 (en) * 2005-12-19 2009-12-01 Genentech, Inc. Method for using BOC/CDO to modulate hedgehog signaling
WO2008121102A2 (en) * 2006-02-21 2008-10-09 The Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
WO2007126455A2 (en) 2006-04-05 2007-11-08 Genentech, Inc. Method for using boc/cdo to modulate hedgehog signaling
CN103435694A (zh) * 2006-10-31 2013-12-11 美国政府卫生与公共服务部 Smoothened多肽及使用方法
EP2121626A1 (de) * 2006-12-15 2009-11-25 Pfizer Products Inc. Benzimidazolderivate
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
CL2008001821A1 (es) 2007-06-20 2009-03-13 Sirtris Pharmaceuticals Inc Compuestos derivados de imidazo[2,1-b]-tiazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de diabetes, sindrome metabolico, resistencia a la insulina, entre otras.
TW200916472A (en) 2007-06-20 2009-04-16 Sirtris Pharmaceuticals Inc Sirtuin modulating compounds
KR101143246B1 (ko) 2007-06-29 2012-05-18 화이자 인코포레이티드 벤즈이미다졸 유도체
JP2011502984A (ja) * 2007-11-01 2011-01-27 サートリス ファーマシューティカルズ， インコーポレイテッド サーチュインモジュレーターとしてのアミド誘導体
CA2705138A1 (en) * 2007-11-08 2009-05-14 Sirtris Pharmaceuticals, Inc. Solubilized thiazolopyridines
AU2008345097A1 (en) 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
FR2930552B1 (fr) * 2008-04-24 2012-10-12 Centre Nat Rech Scient N-acylthiourees et n-acylurees inhibiteurs de la voie de signalisation des proteines hedgehog
WO2010021381A1 (ja) * 2008-08-22 2010-02-25 武田薬品工業株式会社 縮合複素環誘導体およびその用途
EP2617414A3 (de) * 2008-10-01 2013-11-06 Novartis AG Geglätteter Antagonismus zur Behandlung von Erkrankungen im Zusammenhang mit dem Hedgehog-Signalweg
EP2376502B1 (de) 2008-12-19 2015-06-17 GlaxoSmithKline LLC Thiazolopyridin-sirtuin-modulierende verbindungen
JP2012529449A (ja) * 2009-06-11 2012-11-22 シエナ ビオテク ソシエタ ペル アチオニ ヘッジホッグ経路アンタゴニストおよびそれらの治療的応用
AR077014A1 (es) * 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
FR2948367A1 (fr) * 2009-07-24 2011-01-28 Centre Nat Rech Scient Derives d'acyl-guanidines modulateurs de la voie de signalisation des proteines hedgehog
JP6141015B2 (ja) 2009-08-05 2017-06-07 インフィニティ ファーマスーティカルズ、インク． シクロパミン類似体の酵素によるアミノ基転移
PL2470173T3 (pl) 2009-08-25 2016-11-30 Leczenie skojarzone nanocząstkowymi kompozycjami taksanu i inhibitorów hedgehog
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
US9394313B2 (en) 2010-09-14 2016-07-19 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
TWI617559B (zh) * 2010-12-22 2018-03-11 江蘇恆瑞醫藥股份有限公司 ２－芳基咪唑并［１，２－ｂ］嗒．２－苯基咪唑并［１，２－ａ］吡啶，和２－苯基咪唑并［１，２－ａ］吡衍生物
US9708299B2 (en) 2011-01-03 2017-07-18 Genentech, Inc. Hedgehog antagonists having zinc binding moieties
TWI674262B (zh) 2011-01-10 2019-10-11 美商英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式
WO2013012915A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
MX2014000648A (es) 2011-07-19 2014-09-25 Infinity Pharmaceuticals Inc Compuestos heterociclicos y sus usos.
KR20140075693A (ko) 2011-08-29 2014-06-19 인피니티 파마슈티칼스, 인코포레이티드 헤테로사이클릭 화합물 및 그의 용도
WO2013049332A1 (en) 2011-09-29 2013-04-04 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
KR102111936B1 (ko) 2011-11-25 2020-05-18 스미또모 가가꾸 가부시끼가이샤 망막 조직 및 망막 관련 세포의 제조 방법
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN103570625A (zh) * 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
EP2914296B2 (de) 2012-11-01 2021-09-29 Infinity Pharmaceuticals, Inc. Behandlung von krebs mit pi3-kinase-isoformmodulatoren
CA2893133A1 (en) 2012-11-29 2014-06-05 Strasspharma Llc Methods of modulating follicle stimulating hormone activity
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US20160024051A1 (en) 2013-03-15 2016-01-28 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9233961B2 (en) 2013-03-15 2016-01-12 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
SG11201509842SA (en) 2013-05-30 2015-12-30 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
WO2015036405A1 (en) 2013-09-10 2015-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for diagnosing and treating basal cell carcinoma
MX2021012208A (es) 2013-10-04 2023-01-19 Infinity Pharmaceuticals Inc Compuestos heterocíclicos y usos de los mismos.
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015061204A1 (en) 2013-10-21 2015-04-30 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015073691A1 (en) 2013-11-14 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of bmp signaling
TWI674263B (zh) 2013-12-19 2019-10-11 瑞士商諾華公司 用於治療寄生蟲疾病之化合物及組合物
NZ724368A (en) 2014-03-19 2023-07-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
CN104151250B (zh) * 2014-07-22 2016-08-31 大连理工大学 一类含苯并咪唑基团的二芳基酰胺类化合物及其合成和应用
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA2988289C (en) 2015-06-04 2023-12-05 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
US10584118B2 (en) * 2015-06-22 2020-03-10 Actelion Pharmaceuticals Ltd NADPH oxidase 4 inhibitors
EP4585268A3 (de) 2015-09-14 2025-10-15 Twelve Therapeutics, Inc. Feste formen von isochinolinonderivaten, herstellungsverfahren, zusammensetzungen damit und verfahren zur verwendung davon
US20170231968A1 (en) 2016-02-11 2017-08-17 PellePharm, Inc. Method for relief of and treatment of pruritus
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
RU2754507C2 (ru) 2016-06-24 2021-09-02 Инфинити Фармасьютикалз, Инк. Комбинированная терапия
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
CN107056723A (zh) * 2017-04-21 2017-08-18 云南大学 一种具有抑制血管内皮生长因子受体信号传导的化合物
JP7323457B2 (ja) 2017-05-18 2023-08-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 肥満細胞疾患の処置のための方法及び医薬組成物
US12605387B2 (en) 2020-07-24 2026-04-21 Secura Bio, Inc. Treatment of cancers using PI3 kinase isoform modulators
CN112511569B (zh) * 2021-02-07 2021-05-11 杭州筋斗腾云科技有限公司 网络资源访问请求的处理方法、系统及计算机设备
CN115477615B (zh) * 2022-10-17 2024-06-18 黄山学院 N-(3-(苯并咪唑-2-基)苯基)酰胺类化合物及其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3164603A (en) 1965-01-05 xnhcox
DE883284C (de) 1938-11-27 1953-07-16 Hoechst Ag Verfahren zur Erzeugung von Azofarbstoffen auf Gebilden aus synthetischen hoehermolekularen Polyamidverbindungen oder auf Faser-gemischen, die Faserstoffe aus den Polyamidverbindungen enthalten
US2547307A (en) 1948-11-09 1951-04-03 Gen Aniline & Film Corp Yellow diffusion-fast color formers of the benzimidazole class
FR998985A (de) 1948-11-09 1952-01-24
US2768894A (en) 1954-04-30 1956-10-30 Gen Aniline & Film Corp Photographic element with emulsion layer containing color former and wetting agent
DE1079762B (de) 1955-09-07 1960-04-14 Bayer Ag Verfahren zur Herstellung von Kuepenfarbstoffen der Thiazol- und Oxazolreihe
DE1282821B (de) 1960-07-15 1968-11-14 Natmar Inc Fluoreszierende Markierungsmittel
US3162642A (en) 1960-07-15 1964-12-22 Nat Marking Mach Co Fluorescent pigments
US5641764A (en) 1989-03-31 1997-06-24 Peter Maccallum Institute Halogenated DNA ligand radiosensitizers for cancer therapy
CH685875A5 (fr) 1991-04-26 1995-10-31 Pierre Baudet Les N-phényl-benzamides protecteurs contre les effets nocifs de la lumière ultra-violette
US5277839A (en) 1992-06-03 1994-01-11 Litton Industrial Automation Automated Vehicles Guidepath material
AU673569B2 (en) 1992-12-02 1996-11-14 Pfizer Inc. Catechol diethers as selective PDE-IV inhibitors
JP3015998B2 (ja) 1993-08-31 2000-03-06 キヤノン株式会社 液晶性化合物、それを含む液晶組成物、該液晶組成物を用いた液晶素子、液晶装置、並びに表示方法
US5496826A (en) 1994-09-02 1996-03-05 Bristol-Myers Squibb Company Pharmaceutical methods of using heterocyclic derivatives of N-phenylamides
US5563143A (en) 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
US5821258A (en) 1994-12-27 1998-10-13 Mitsui Chemicals, Inc. Phenylbenzimidazole derivatives
JP3223090B2 (ja) * 1994-12-27 2001-10-29 三井化学株式会社 フェニルベンズイミダゾール誘導体
GB9503946D0 (en) 1995-02-28 1995-04-19 Cancer Res Campaign Tech Benzazole compounds
WO1998017267A1 (en) 1996-10-23 1998-04-30 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
EP0946587A2 (de) 1996-12-16 1999-10-06 Fujisawa Pharmaceutical Co., Ltd. Amindverbindungen und ihre verwendung als inhibitoren der bitric-oxid-synthase
US5994394A (en) 1997-03-21 1999-11-30 Industrial Technology Research Institute Polyheterocyclic compounds
US6649631B1 (en) 1997-10-23 2003-11-18 The Board Of Regents Of The University Of Texas System Compositions and methods for treating bone deficit conditions
US6046229A (en) 1998-01-06 2000-04-04 Industrial Technology Research Institute Polyaryl antitumor agents
US6303645B1 (en) * 1998-05-22 2001-10-16 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
RU2236220C2 (ru) 1998-05-22 2004-09-20 Аванир Фармасьютикэлз Аналоги бензимидазола в качестве понижающих регуляторов ige
US6919366B2 (en) 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
CA2333770A1 (en) 1998-06-04 1999-12-09 Abbott Laboratories Cell adhesion-inhibiting antinflammatory compounds
WO2000035886A2 (en) 1998-12-18 2000-06-22 Axys Pharmaceuticals, Inc. (hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors
US6291516B1 (en) * 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
AU780846B2 (en) * 1999-09-16 2005-04-21 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
GB0007934D0 (en) * 2000-03-31 2000-05-17 Darwin Discovery Ltd Chemical compounds
JP2004503553A (ja) * 2000-06-14 2004-02-05 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー ６，５−縮合二環式複素環
BR0208010A (pt) 2001-03-12 2004-12-21 Avanir Pharmaceuticals Composto de benzimidazol para modulação de ige e inibição de proliferação celular
EP1807074B1 (de) 2004-11-03 2013-10-23 Curis, Inc. Mediatoren von hedgehog-signalwegen, zusammensetzungen und verwendungen in zusammenhang damit

Also Published As

Publication number Publication date
DE60233823D1 (de) 2009-11-05
BR0211513A (pt) 2005-08-30
NZ530580A (en) 2007-02-23
WO2003011219A3 (en) 2004-09-23
AU2002327390B2 (en) 2008-06-26
EP1482928A2 (de) 2004-12-08
EP1482928B1 (de) 2009-09-23
EP1482928A4 (de) 2005-10-12
IL159858A0 (en) 2004-06-20
PL366799A1 (en) 2005-02-07
CA2455100C (en) 2013-05-28
US20130190350A1 (en) 2013-07-25
EA200400080A1 (ru) 2005-02-24
US20050085519A1 (en) 2005-04-21
MXPA04000803A (es) 2004-05-21
US8354397B2 (en) 2013-01-15
EA007339B1 (ru) 2006-08-25
US8772275B2 (en) 2014-07-08
JP2005507860A (ja) 2005-03-24
NO20040342L (no) 2004-03-26
JP4658473B2 (ja) 2011-03-23
WO2003011219A2 (en) 2003-02-13
CA2455100A1 (en) 2003-02-13
CN1638765A (zh) 2005-07-13
KR20040031782A (ko) 2004-04-13

Similar Documents

Publication Publication Date Title
ATE443518T1 (de) Vermittler von igel-signalpfaden, zusammensetzungen und relevante verwendungszwecke
ATE404200T1 (de) Modulatoren von hedgehog signalpfaden, zusammensetzungen und verwandte verwendungen
DE60027749D1 (de) Vermittler von "hedgehog" übermittelnden bahnen, dazugehörige zusammenetzungen und verwendungen
WO2002030421A3 (en) Mediators of hedgehog signaling pathways, compositions and uses related thereto
WO2001019800A3 (en) Mediators of hedgehog signaling pathways, compositions and uses related thereto
WO2002038806A3 (de) Nachweis von nukleinsäure-polymorphismen
ATE305786T1 (de) Kleine organische moleküle als regulatoren der zellproliferation
WO2000041545A3 (en) Regulators of the pct or smoothened pathway, compositions and uses related thereto
WO2005033288A3 (en) Hedgehog pathway antagonists
WO2002048115A3 (en) Quinazolinones and pyridinopyrimidinones for controlling invertebrate pests
NL300242I2 (nl) Omega-carboxyaryl gesubstitueerde difenylureums als raf kinaseremmers.
SG151250A1 (en) Substituted 6-cyclohexylalkyl substituted 2-quinolinones and 2- quinoxalinones as poly(adp-ribose) polymerase inhibitors
MXPA02011368A (es) Combinaciones de productos activos con propiedades insecticidas y acaricidas.
ATE234301T1 (de) Neue benzonaphtyridin-n-oxide
DE60216278D1 (de) Polyoxyalkylen-ammoniumsalze und ihre verwendung als antistatika
EA200700042A1 (ru) РАСПЫЛЯЕМЫЕ В ВИДЕ АЭРОЗОЛЯ СУСПЕНЗИОННЫЕ КОМПОЗИЦИИ С TG 227ea ИЛИ TG 134a В КАЧЕСТВЕ ПРОПЕЛЛЕНТА
WO2005002508A3 (en) Macromolecular platinum chelates
DE60138903D1 (de) N-(1,2,4-triazoloazinyl)thiophensulfonamid-verbindungen als herbizide
EP1262195A4 (de) Vasoaktieve agentia
DK1366151T3 (da) pRNA-kimærer
ATE390420T1 (de) 2-substituierte pyrimidine und ihre verwendung als pestizide
FR2850578B1 (fr) Utilisation de n-arylmethylene ethylenediaminetriacetates, n-arylmethyleneiminodiacetates ou n,n'-diarylmethylene ethylenediamineacetates comme donneurs de no
DK1613772T3 (da) Fremgangsmåde til bestemmelse af tilstanden af jord
BR0311590A (pt) Agonistas de brs-3 não-peptìdicos
ATE397583T1 (de) Abiotische heparinantagonisten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties